Clinical Trial Search

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -0.46; -0.25; -0.71; -1.08 Percentage of HbA1c in the blood — p=0.2968

Primary: Proportion of Patients With PSA Response — 0.293; 0.098; 0.042 Proportion of participants

Primary: Change in Ln(Bacterial Colony Count) From Pre-antibiotic Administration to Post Study Medication Swabs — -0.14; -0.52 Ln(bacterial colony count)

Primary: Comparison of the Absolute Bioavailability of Two Intranasal Diazepam Formulations. — 69; 96.82; 100 Percentage of Bioavailability

Primary: Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal — 6.99; 7.51 percentage…

Primary: Mean Change in Cortisol Levels From Baseline to Week 24 — 0.187 mg/dL

Primary: Improvement in Prurigo Nodularis — 0; 2 participants

Primary: Number of Subjects Where Hilar Cholangiocarcinomas Could be Visualized Using Gadoxetate Disodium Enhanced Dual Energy CT — 5 participants

Primary: Number of Expectant Mothers Experiencing Adverse Events (AEs) — 7; 6 Participants

Primary: Pre-Lens Non-Invasive Keratograph Break Up Time (PL NIK-BUT) at 8 Hours — 5.28; 3.46; 4.93 seconds

Primary: Time to All-Cause Mortality — 440; 423; 439 Number of deaths

Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants

Primary: Apnea Hypopnea Index (AHI) — 30.3; 32.3; 39.1 events per hour

Primary: Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4 — 73 percentage of participants

Primary: Percent of Participants With Progression Free Survival at 1 Year — 58 percentage of participants